Trials / Unknown
UnknownNCT05750290
CKD-702 Plus Irinotecan in Gastric Cancer
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- National Cancer Center, Korea · Other Government
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-702 in combination with irinotecan | CKD-702 and irinotecan will be intravenously administered every 2 weeks. |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
- First posted
- 2023-03-01
- Last updated
- 2023-03-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05750290. Inclusion in this directory is not an endorsement.